🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
PHV
$PHVS
🔒 US EquitiesPharvaris NV
AVG HISTORICAL GAP
-0.98%
MAX GAP RECORD
-5.77%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $PHVS
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$PHVS
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 12, 2026 Earnings Release 2026-11-12 (BEFORE OPEN (07:00)) | 🔮 UPCOMING 🔒 |
| Aug 12, 2026 Earnings Release 2026-08-12 (AFTER CLOSE) |
+0.11%
|
| Apr 02, 2026 Earnings Release 2026-04-02 (BEFORE OPEN) |
-4.52%
|
| Nov 12, 2025 Earnings Release 2025-11-12 (BEFORE OPEN) |
-0.46%
|
| Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE) |
+2.32%
|
| Apr 07, 2025 Earnings Release 2025-04-07 (BEFORE OPEN) |
-1.54%
|
| Nov 13, 2024 Earnings Release 2024-11-13 (AFTER CLOSE) |
-0.15%
|
| Aug 14, 2024 Earnings Release 2024-08-14 (BEFORE OPEN) |
+2.41%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
2.0%
Bullish Gaps (2)
Bearish Gaps (5)
Neutral / Flat (4)
📖 Intelligence Summary
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗